Dawnrays Pharmaceutical Holdings Ltd. (HK:2348) has released an update.
Dawnrays Pharmaceutical Holdings Ltd. announced the appointment of Ms. Yu Liwei as the new CEO, effective from 13 September 2024. Ms. Yu, with a background in Biological Pharmaceutics and a history of managerial roles within the company, steps into the leadership position with a two-year contract. Her compensation includes an annual salary of HKD2,400,000 plus potential discretionary bonuses based on the company’s performance.
For further insights into HK:2348 stock, check out TipRanks’ Stock Analysis page.